Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis a systematic review and meta-analysis

Clinical Nuclear Medicine

Volumn 41, Issue 7, 2016, Pages e327-e339

  Tang, Reuben ^a   Wang, Jeffrey Tzu Yu ^a   Wang, Louis ^a   Le, Ken ^a   Huang, Yeqian ^a   Hickey, Adam James ^a   Emmett, Louise ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

18F FDG PET CT; Cardiac sarcoidosis; Diagnostic accuracy; Meta analysis

Indexed keywords

CARBOHYDRATE; FAT; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; THALLIUM CHLORIDE TL 201; ANTICOAGULANT AGENT; RADIOPHARMACEUTICAL AGENT;

CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFIDENCE INTERVAL; CONTRAST ENHANCEMENT; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; DRUG INFUSION; EMBASE; HEART; HEART SCINTISCANNING; HUMAN; IMAGE QUALITY; LIPID DIET; LOW CARBOHYDRATE DIET; MEDLINE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ODDS RATIO; RANDOM FOREST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; CARDIOMYOPATHIES; DIAGNOSTIC IMAGING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; REGRESSION ANALYSIS;

ANTICOAGULANTS; CARDIOMYOPATHIES; FLUORODEOXYGLUCOSE F18; HEPARIN; HUMANS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS; ROC CURVE; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84949481756     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001063     Document Type: Review

References (38)

1. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet. 2014;383: 1155-1167.
2. Terasaki F, Ishizaka N. Deterioration of cardiac function during the progression of cardiac sarcoidosis: diagnosis and treatment. Intern Med. 2014;53: 1595-1605.
3. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-1211.
4. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63: 86-108.
5. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167-172.
6. Torchio M, Bottaro G, Bertolino G, et al. Late-onset sarcoidosis in a patient with gastric mucosa-associated lymphoid tissue non-Hodgkin lymphoma: a case report. Oncol Lett. 2014;8:1299-1301.
7. Wicks E, Menezes L, Pantazis A, et al. 135 Novel hybrid positron emission tomography-magnetic resonance (PET-MR) multi-modality inflammatory imaging has improved diagnostic accuracy for detecting cardiac sarcoidosis. Heart. 2014;100 Suppl 3:A80.
8. Japanese Society of Sarcoidosis and Other Granulomatous Disorders. Diagnostic Standard and Guideline for Sarcoidosis. Tokyo: Japanese Ministry of Health, Labour and Welfare; 2006:6.
9. Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21:925-939.
10. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2- deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538-1543.
11. Manabe O, Yoshinaga K, Ohira H, et al. Right ventricular (18)F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis. Ann Nucl Med. 2014;28:656-663.
12. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773-1783.
13. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241-248.
14. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989-1998.
15. Langah R, Spicer K, Gebregziabher M, et al. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801-810.
16. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3:1219-1228.
17. Ambrosini V, Zompatori M, Fasano L, et al. (18)F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med. 2013;38:e171-e177.
18. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329-336.
19. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
20. The Cochrane Collaboration. Review Manager (RevMan). 5.3 ed.Copenhagen, Denmark: The Nordic Cochrane Centre; 2012.
21. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software formeta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
22. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.
23. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030-1036.
24. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571-1576.
25. Matoh F, Satoh H, Shiraki K, et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol. 2008;51:179-188.
26. Ohira H, Tsujino I, Ishimaru S, et al.Myocardial imaging with 18F-fluoro-2- deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933-941.
27. Lebasnier A, Lasnon C, Legallois D, et al. Diagnostic value of cardiac dynamic FDG-PET/CT for cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2013;40:S138-S139.
28. Soussan M, Brillet PY, Nunes H, et al. Clinical value of a high-fat and lowcarbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20:120-127.
29. Kaneta T, Hakamatsuka T, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med. 2006;20: 203-208.
30. Isiguzo M, Brunken R, Tchou P, et al. Metabolism-perfusion imaging to predict disease activity in cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:50-55.
31. Cherkes A, Gordon RS. The liberation of lipoprotein lipase by heparin from adipose tissue incubated in vitro. J Lipid Res. 1959;1:97-101.
32. Abozguia K, Clarke K, Lee L, et al. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med. 2006;3:490-498.
33. Bing R, Siegel A, Ungar I, et al. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16:504-515.
34. Fujita S, Nagamachi S, Umemura Y, et al. Usability of the heparin appositional whole body FDG PET-new methods to reduce cardiac physiological accumulation. Eur J Nucl Med Mol Imaging. 2011;38:S359.
35. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151-W156.
36. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4:1.
37. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20: 578-583.
38. Cochrane Collaboration. Cochrane Handbook. Copenhagen, Denmark: The Cochrane Collaboration; 2014.